Fidia Pharma USA partners with AEONSurgical to expand its US sales presence

AEONSurgical’s team will sell Hyalgan® alongside Fidia’s direct sales force.

PARSIPPANY, N.J., & SAN ANTONIO, TX; September 15, 2014, -- Fidia Pharma USA Inc., a wholly-owned subsidiary of Fidia Farmaceutici SpA, an international specialty pharmaceutical company and recognized leader in hyaluronic acid-based products, announced today the completion of a sales and marketing agreement with AEONSurgical, a leading group of independent sales representatives to physician and hospital customers across the US.

Effective September 15, 2014, AEONSurgical’s team will sell Hyalgan® alongside Fidia’s direct sales force. Oscar N. Obledo, CEO & Founder of AEONSurgical, said, “Our partnership with Fidia Pharma USA demonstrates our continued commitment to working with Joint Healthcare manufacturers who develop innovative technologies that assist in positive outcomes for Osteoarthritis patients, while also providing an economical solution for hospitals and physicians."

“AEONSurgical target focus, presence and experience in the Biologics /Medical Device, Joints (Hips/Knees), Podiatry, Spine, Sports Medicine, Wound Care/Closure market provides significant opportunity of synergy with our organization ” says Mr. Aldo Donati, President of Fidia Pharma USA Inc. “ and strengthens Fidia’s already robust presence in the US market.”

About Hyalgan®
Hyalgan® (Sodium hyaluronate), intra-articular injections are approved for the treatment of pain in osteoarthritis (OA) of the knee in patients who have failed to adequately respond to conservative nonpharmacologic therapy and to simple analgesic. Hylagan ® provides long-term pain relief with repeat use. For more information and full prescribing information please visit www.hyalgan.com

About AEONSurgical
AEONSurgical, based in San Antonio, TX, is a medical and pharmaceutical products sales organization comprised of independent sales representatives with customers across the United States and select international regions. The organization partners with manufacturers to expand physician and hospital accounts and increase sales. AEONSurgical’s team spans across the United States and targeted areas around the world who are medical device and pharmaceutical product experts. The company’s mission is to provide hope of healing to each patient treated by the quality products provided by their manufacturer partners. For more information, please visit http://www.aeonsurgical.com.

About Fidia Pharma USA Inc.
Fidia Pharma USA Inc., headquartered in Parsippany, NJ, is a wholly-owned subsidiary of the multinational specialty pharmaceutical company Fidia Farmaceutici SpA. Fidia Pharma USA is focused on establishing and expanding Fidia’s position in the US and Canadian markets, while upholding the company’s mission to provide consumers with innovative products that offer quality, safety and performance. Drawing on the strengths of the parent company, Fidia Pharma USA's product portfolio focuses primarily on therapeutic areas such as Joint Healthcare and Advanced Wound Care. For more information, please visit http://www.fidiapharma.us.


Find out more about Fidia’s product portfolio:

Go to the website


Fidia Farmaceutici has a specific module dedicated to Pharmaco-Vigilance in order to promptly reporting of suspected adverse reactions. If you suspect that you have had an adverse reaction while taking one of our products or you have found defects

Key Business Areas

Fidia operates in numerous therapeutic areas, providing specific, innovative treatments for commonly occurring pathologies with major socio-economic impact, namely:

- joint care
- ophthalmology
- active wound care
- neuroscience
- aesthetic medicine